Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease

Bibliography

• Oppenheimer DR. Disease of the basal ganglia, cerebellum and motor neurons. In: Adams JH, Duchen LW, editors, Greenfield's Neuropathology. 4th edition. Wiley, New York; 1984. p. 699-747
   Google Scholar
• Braak H, Braak E, Yilmazer D, Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 1995;46:15-31
   Google Scholar
• Fabbrini G, Brotchie JM, Grandas F, Levodopa-induced dyskinesias. Mov Disord 2007;22(10):1379-89, quiz 523
   Google Scholar
• Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007;64(8):1083-8
   Google Scholar
• Sampaio C, Rascol O. Disease-modifying strategies in Parkinson's disease. In: Jankovic J, editor, Parkinson's disease and movement disorders. 5th edition. Lippincott, Williams and Wilkins, Philadelphia; 2001. p. 103-9
   Google Scholar
• Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain 2004;127(Pt 8):1693-705
   Google Scholar
• Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287(13):1653-61
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ, Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54(1):93-101
   PubMed Web of Science ®Google Scholar
• de la Fuente-Fernandez R, Schulzer M, Mak E, Sossi V. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. Parkinsonism Relat Disord 2010;16(6):365-9
   Google Scholar
• Fahn SERL. Unified Parkinson's disease rating scale. In: Fahn SERL, Marsend CD, Goldstein M, Calne DB, editors, Recent developments in Parkinson's disease: Macmillan Healthcare Information; 1987. p. 153-63
   Google Scholar
• Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson study group. N Engl J Med 1993;328(3):176-83
   PubMed Web of Science ®Google Scholar
• Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32(6):795-8
   Google Scholar
• Olanow CW, Hauser RA, Gauger L, The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38(5):771-7
   PubMed Web of Science ®Google Scholar
• Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson study group. Ann Neurol 1996;40(1):99-107
   Google Scholar
• Shults CW, Oakes D, Kieburtz K, Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59(10):1541-50
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498-508
   PubMed Web of Science ®Google Scholar
• Hauser RA, Auinger P, Oakes D. Levodopa response in early Parkinson's disease. Mov Disord 2009;24(16):2328-36
   Google Scholar
• Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59(3):559-62
   Google Scholar
• Olanow CW, Rascol O, Hauser R, A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• D'Agostino RB Sr. The delayed-start study design. N Engl J Med 2009;361(13):1304-6
   Google Scholar
• Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010;74(14):1143-8
   Google Scholar
• Olanow CW, Rascol O. The delayed-start study in Parkinson disease: can't satisfy everyone. Neurology 2010;74(14):1149-50
   Google Scholar
• Ahlskog JE, Uitti RJ. Reply to Drs. Olanow and Rascol. Neurology 2010;74(14):1151
   Google Scholar
• Schapira AH, Albrecht S, Barone P, Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord 2010;25(11):1627-32
   Google Scholar
• Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-301
   Google Scholar
• Kish SJ, Shannak K, Rajput A, Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 1992;58(2):642-8
   Google Scholar
• Colloby SJ, Williams ED, Burn DJ, Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2005;32(10):1176-85
   Google Scholar
• Nurmi E, Ruottinen HM, Kaasinen V, Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 2000;47(6):804-8
   Google Scholar
• Bruck A, Aalto S, Nurmi E, Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 2006;21(7):958-63
   Google Scholar
• Pirker W, Holler I, Gerschlager W, Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord 2003;18(11):1266-72
   Google Scholar
• Morrish PK, Rakshi JS, Bailey DL, Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64(3):314-19
   Google Scholar
• Frost JJ, Rosier AJ, Reich SG, Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34(3):423-31
   Google Scholar
• Marek K, Innis R, van Dyck C, [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57(11):2089-94
   Google Scholar
• Schulzer M, Lee CS, Mak EK, A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 1994;117(Pt 3):509-16
   Google Scholar
• The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18(7):738-50
   Google Scholar
• Shulman LM, Gruber-Baldini AL, Anderson KE, The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010;67(1):64-70
   Google Scholar
• Goetz CG, Wuu J, McDermott MP, Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008;23(5):690-9
   Google Scholar
• Poewe W. The natural history of Parkinson's disease. J Neurol 2006;253(Suppl 7):VII2-6
   PubMedGoogle Scholar
• Muller J, Wenning GK, Jellinger K, Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 2000;55(6):888-91
   Google Scholar
• Maier Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl 1983;19:253-64
   Google Scholar
• Uitti RJ, Ahlskog JE, Maraganore DM, Levodopa therapy and survival in idiopathic Parkinson's disease: olmsted county project. Neurology 1993;43(10):1918-26
   Google Scholar
• Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001;8(2):95-100
   Google Scholar
• Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20(2):190-9
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8(5):464-74
   Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-42
   PubMedGoogle Scholar
• Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord 2000;15(3):479-84
   Google Scholar
• Roos RA, Jongen JC, van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord 1996;11(3):236-42
   Google Scholar
• Goetz CG, Poewe W, Rascol O, Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19(9):1020-8
   Google Scholar
• Louis ED, Tang MX, Cote L, Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999;56(3):334-7
   Google Scholar
• Harrison MB, Wylie SA, Frysinger RC, UPDRS activity of daily living score as a marker of Parkinson's disease progression. Mov Disord 2009;24(2):224-30
   Google Scholar
• Factors impacting on quality of life in Parkinson's disease. results from an international survey. Mov Disord 2002;17(1):60-7
   Google Scholar
• Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006;248(1-2):151-7
   Google Scholar
• Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69(3):308-12
   Google Scholar
• Marras C, McDermott MP, Rochon PA, Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord 2008;23(5):653-9, quiz 776
   Google Scholar
• Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48(8):938-42
   Google Scholar
• Schrag A, Dodel R, Spottke A, Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007;22(7):938-45
   Google Scholar
• van Hilten JJ, van der Zwan AD, Zwinderman AH, Roos RA. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale. Mov Disord 1994;9(1):84-8
   Google Scholar
• Martinez-Martin P, Gil-Nagel A, Unified Parkinson's Disease Rating Scale characteristics and structure. The cooperative multicentric group. Mov Disord 1994;9(1):76-83
   Google Scholar
• Goetz CG, Fahn S, Martinez-Martin P, Movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22(1):41-7
   Google Scholar
• Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41(1):58-64
   Google Scholar
• Antonini A, Moeller JR, Nakamura T, The metabolic anatomy of tremor in Parkinson's disease. Neurology 1998;51(3):803-10
   Google Scholar
• Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson's disease. Brain 2000;123(Pt 9):1767-83
   Google Scholar
• Zweig RM, Jankel WR, Hedreen JC, The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 1989;26(1):41-6
   Google Scholar
• Lazic SE, Mason SL, Michell AW, Barker RA. Visualising disease progression on multiple variables with vector plots and path plots. BMC Med Res Methodol 2009;9:32
   Google Scholar
• Levy G, Louis ED, Cote L, Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 2005;62(3):467-72
   Google Scholar
• Delval A, Snijders AH, Weerdesteyn V, Objective detection of subtle freezing of gait episodes in Parkinson's disease. Mov Disord 2010;25(11):1684-93
   Google Scholar
• Zampieri C, Salarian A, Carlson-Kuhta P, The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease. J Neurol Neurosurg Psychiatry 2010;81(2):171-6
   Google Scholar
• Cox DR, Oakes D. Analysis of Survival Data. CRC Press LLC, New York; 1984
   Google Scholar
• Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 2002;17(5):867-76
   Google Scholar
• Schrag A, Spottke A, Quinn NP, Dodel R. Comparative responsiveness of Parkinson's disease scales to change over time. Mov Disord 2009;24(6):813-18
   Google Scholar
• Rudick RA, Miller DM. Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment. CNS Drugs 2008;22(10):827-39
   Google Scholar
• Evans JR, Barker RA. Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 2008;12(4):437-47
   Google Scholar
• Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs 2010;24(3):177-92
   PubMed Web of Science ®Google Scholar
• Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 2009;1792(7):688-702
   Google Scholar
• Lang AE, Gill S, Patel NK, Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59(3):459-66
   Google Scholar
• Allan LE, Petit GH, Brundin P. Cell transplantation in Parkinson's disease: problems and perspectives. Curr Opin Neurol 2010;23(4):426-32
   Google Scholar
• Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson study group. Arch Neurol 2000;57(3):369-72
   Google Scholar
• Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005;65(9):1436-41
   Google Scholar
• Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007;64(9):1242-6
   Google Scholar
• Goris A, Williams-Gray CH, Clark GR, Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007;62(2):145-53
   Google Scholar
• Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010;16(2):79-84
   Google Scholar